GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc.
(Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024 . The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 ( North America ) or 1-646-357-8785 (International).
Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.
com/events-presentations . Precigen: Advancing Medicine with Precision TM Precigen (Nasdaq: PGEN ) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinic.